Junxiang Luo

901 total citations · 1 hit paper
29 papers, 640 citations indexed

About

Junxiang Luo is a scholar working on Statistics and Probability, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Junxiang Luo has authored 29 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Statistics and Probability, 9 papers in Surgery and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Junxiang Luo's work include Statistical Methods in Clinical Trials (9 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Diabetes Management and Research (7 papers). Junxiang Luo is often cited by papers focused on Statistical Methods in Clinical Trials (9 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Diabetes Management and Research (7 papers). Junxiang Luo collaborates with scholars based in United States, Netherlands and France. Junxiang Luo's co-authors include Yongming Qu, David S. Small, Kenneth J. Winters, Joseph A. Jakubowski, Stephen J. Ruberg, Annette M. Chang, Ying G. Li, Gilles Montalescot, Jurriën M. ten Berg and David Erlinge and has published in prestigious journals such as Nature, Journal of the American College of Cardiology and Diabetes Care.

In The Last Decade

Junxiang Luo

27 papers receiving 623 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia

2024 55 citations Dwight D. Koeberl, Andreas Schulze et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junxiang Luo United States	14	350	239	138	95	94	29	640
Qingmiao Shao China	12	335 1.0×	92 0.4×	148 1.1×	44 0.5×	153 1.6×	18	601
Jakub Gumprecht Poland	11	418 1.2×	160 0.7×	241 1.7×	40 0.4×	82 0.9×	25	733
Shaozhao Zhang China	13	235 0.7×	82 0.3×	76 0.6×	14 0.1×	61 0.6×	68	458
Clay Cauthen United States	7	216 0.6×	91 0.4×	18 0.1×	15 0.2×	82 0.9×	15	459
Michael Stuart Garfinkle Canada	4	625 1.8×	61 0.3×	59 0.4×	51 0.5×	35 0.4×	5	721
Cezary Sosnowski Poland	8	316 0.9×	211 0.9×	199 1.4×	51 0.5×	117 1.2×	24	559
Maya Salameh United States	10	178 0.5×	174 0.7×	46 0.3×	23 0.2×	32 0.3×	24	437
SG Thompson United Kingdom	7	234 0.7×	103 0.4×	26 0.2×	5 0.1×	83 0.9×	13	674
Patrice Nault Canada	6	213 0.6×	474 2.0×	85 0.6×	41 0.4×	16 0.2×	14	578
Kristin Ohneberg Germany	6	143 0.4×	291 1.2×	538 3.9×	3 0.0×	222 2.4×	10	692

Countries citing papers authored by Junxiang Luo

Since Specialization

Citations

This map shows the geographic impact of Junxiang Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junxiang Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junxiang Luo more than expected).

Fields of papers citing papers by Junxiang Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junxiang Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junxiang Luo. The network helps show where Junxiang Luo may publish in the future.

Co-authorship network of co-authors of Junxiang Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Junxiang Luo. A scholar is included among the top collaborators of Junxiang Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junxiang Luo. Junxiang Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Rui, Junxiang Luo, Yanling Wu, et al.. (2025). Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials. Radiotherapy and Oncology. 207. 110867–110867.

Koeberl, Dwight D., Andreas Schulze, Neal Sondheimer, et al.. (2024). Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia. Nature. 628(8009). 872–877. 55 indexed citations breakdown →

Quan, Hui, et al.. (2023). Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint. Pharmaceutical Statistics. 22(4). 633–649. 4 indexed citations

Qu, Yongming, Junxiang Luo, Elena Polverejan, et al.. (2023). CITIES: Clinical trials with intercurrent events simulator. Biometrical Journal. 66(1). e2200103–e2200103. 2 indexed citations

Liu, Jingjing, et al.. (2022). Microbial metabolites and heart failure: Friends or enemies?. Frontiers in Microbiology. 13. 956516–956516. 7 indexed citations

Qu, Yongming, Junxiang Luo, & Stephen J. Ruberg. (2020). Implementation of tripartite estimands using adherence causal estimators under the causal inference framework. Pharmaceutical Statistics. 20(1). 55–67. 15 indexed citations

Qu, Yongming, Haoda Fu, Junxiang Luo, & Stephen J. Ruberg. (2019). A General Framework for Treatment Effect Estimators Considering Patient Adherence. Statistics in Biopharmaceutical Research. 12(1). 1–18. 19 indexed citations

Buse, John B., Helena W. Rodbard, Carlos Trescolí Serrano, et al.. (2015). Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. Diabetes Care. 39(1). 92–100. 67 indexed citations

Fu, Haoda, Junxiang Luo, & Yongming Qu. (2014). Hypoglycemic events analysis via recurrent time-to-event (HEART) models. Journal of Biopharmaceutical Statistics. 26(2). 280–298. 6 indexed citations

10.

Luo, Junxiang, et al.. (2014). A Clinical Utility Index for Selecting an Optimal Insulin Dosing Algorithm for LY2605541 in Patients with Type 2 Diabetes Pretreated with Basal Insulin. Diabetes Technology & Therapeutics. 16(8). 499–505. 1 indexed citations

11.

Erlinge, David, Paul A. Gurbel, Stefan James, et al.. (2013). Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients. Journal of the American College of Cardiology. 62(7). 577–583. 64 indexed citations

12.

Erlinge, David, Jurriën M. ten Berg, David P. Foley, et al.. (2012). Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients. Journal of the American College of Cardiology. 60(20). 2032–2040. 63 indexed citations

13.

Montalescot, Gilles, Leonardo Bolognese, Dariusz Dudek, et al.. (2011). A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non–ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. American Heart Journal. 161(4). 650–656.e1. 22 indexed citations

14.

Riesmeyer, Jeffrey S., Daniel E. Salazar, Govinda J. Weerakkody, et al.. (2011). Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy. The Journal of Clinical Pharmacology. 52(6). 789–797. 41 indexed citations

15.

Zhu, Baojin, Mark B. Effron, Pandurang M. Kulkarni, et al.. (2011). The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data. Journal of Cardiovascular Pharmacology. 57(3). 317–324. 16 indexed citations

16.

Jakubowski, Joseph A., Ying G. Li, David S. Small, et al.. (2010). A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis. Journal of Cardiovascular Pharmacology. 56(1). 29–37. 39 indexed citations

17.

Sidéris, Georgios, R. Cohen, Catherine Meuleman, et al.. (2009). Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. Thrombosis and Haemostasis. 103(1). 213–223. 109 indexed citations

18.

Luo, Junxiang, Rakesh Shukla, Atin Adhikari, et al.. (2006). Estimating sampling frequency in pollen exposure assessment over time. Journal of Environmental Monitoring. 8(9). 955–955. 3 indexed citations

19.

Shukla, Rakesh, Junxiang Luo, Grace K. LeMasters, Sergey A. Grinshpun, & Dainius Martuzevičius. (2005). Sampling over time: developing a cost effective and precise exposure assessment program. Journal of Environmental Monitoring. 7(6). 603–603. 12 indexed citations

20.

Martuzevičius, Dainius, et al.. (2004). Evaluation and optimization of an urban PM2.5 monitoring network. Journal of Environmental Monitoring. 7(1). 67–67. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact